CAR-T and engineered T cell therapies

Clinical MedicineUpdated Oct 5, 2026Version v1

Evidence

Public papers linked to this topic and used as evidence for gaps, timelines, and knowledge views.

249 papers

Active filtersClassification:Core

Showing 85-96 of total 249 evidence records.

Open a paper to inspect abstract, source links, and topic context.

2026PubMedDirectly related

TCR-JANUS engager proteins enable bispecific targeting to overcome tumor heterogeneity in TCR-T cell therapy.

Cheng C; Liang T; Yao P; Wang W; Chen H; Li X; Tian Y; Wang J; Yan N; Xie D; Qiu F; Tan S

2026PubMedDirectly related

Cutaneous Toxicities of T-Cell-Redirecting Therapies in Multiple Myeloma: An EADV Task Force Position Paper and Practical Recommendations.

Nikolaou V; Koumaki D; Perrot A; Kastritis E; Beylot-Barry M; Sibaud V

Jan 1, 2026Clinical lymphoma, myeloma & leukemia

2026PubMedDirectly related

CART-Cell Therapy in Pediatric Acute Lymphoblastic Leukemia: A Review for General Pediatricians.

Grasso A; Mishra AK; Silva J; Amrolia PJ

Jan 1, 2026Pediatrics

2026PubMedDirectly related

CART-Cell Therapy in Pediatric Acute Lymphoblastic Leukemia: A Review for General Pediatricians.

Grasso A; Mishra AK; Silva J; Amrolia PJ

Jan 1, 2026Pediatrics

2026PubMedDirectly related

Simultaneous gene engineering of T cells with multiple neoantigen-specific T cell receptors for adoptive cell transfer.

Magna M; Levy L; Csomos K; Dinerman AJ; Hakim AA; Levin N; Kim SP; Zacharakis N; Parikh NB; Bui BD; Bhasin A; Beyer RK; Goff SL; Lowery FJ; Rosenberg SA; Krishna S

Jan 1, 2026Molecular therapy. Advances

2026PubMedDirectly related

From cellular therapy to biologics: Non-viral delivery strategies for in vivo CAR-T engineering.

Wu S; Shen Y; Tong X; Nian S; Yang P

Jan 1, 2026Critical reviews in oncology/hematology

2026PubMedDirectly related

[T-cell engagers: a transformative force or a redundant option in B-cell depletion therapy for rheumatic diseases?].

Li QB; Guan X; Mei CL; Xu J

Jan 1, 2026Zhonghua yi xue za zhi

2026PubMedDirectly related

[Efficacy and safety analysis of the salvage treatment for diffuse large B-cell lymphoma after the failure of anti-CD19 CAR-T therapy].

Lu Y; Zhou LL; Ye SG; Yao CY; Wang BT; Liang AB; Li P

Jan 1, 2026Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

2026PubMedDirectly related

[The efficacy and safety of glofitamab combined with polatuzumab vedotin in the treatment of 9 cases of relapsed/refractory diffuse large B-cell lymphoma after failing CAR-T cell therapy].

Zhang H; He XY; Xiao X; Lyu HR; Zhao MF

Jan 1, 2026Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

2026PubMedDirectly related

Chimeric antigen receptor (CAR)-T cell therapy for solid tumors in pediatric patients: current breakthroughs, dilemmas, and strategies.

Mai Y; Wang Z; Wang J; Song M; Xiang T; He Y; Chang AH; Zhang Y

Jan 1, 2026Experimental hematology & oncology

2026PubMedDirectly related

Pretreatment TyG-BMI predicts CD19 CAR-T persistence and prognosis in diffuse large B-cell lymphoma.

Liu Z; Yang R; Chen J; Liu Z; Ding Y; Huang K; Liao Y; Hu L; Pu L; Liu L; Wang J; Tao Q; Xiong S

Jan 1, 2026Frontiers in oncology

2026PubMedDirectly related

A PRK-armed oncolytic adenovirus drives calreticulin exposure for dendritic cell licensing to prime antitumor CD8⁺ T cells and synergizes with anti-PD-1 or CAR-T therapy in colorectal cancer.

Liu Y; Ran B; Kong L; Zhou D; Zhuang Y; Guo C; Ren X; Li J; Yang X; Cui H; Xin Q; Xiao L; Gu X; Wu J; Jiang C

Jan 1, 2026Journal of gastroenterology